Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436227 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome
A Phase 2 study of Von Hippel-Lindau Syndrome, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01436227 is a Phase 2 study of Von Hippel-Lindau Syndrome that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01436227, a Phase 2 study of Von Hippel-Lindau Syndrome, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Pazopanib Hydrochloride
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-01-17 |
| Est. Completion | 2024-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436227
The ClinicalTrials.gov registry entry for NCT01436227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Von Hippel-Lindau Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01436227 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01436227 about?
NCT01436227 is a clinical study titled "Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome". This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with von Hippel-Lindau syndrome. Pazopanib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01436227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-01-17. Estimated completion is 2024-03-13.
What conditions does trial NCT01436227 study?
This clinical trial studies the following conditions: Von Hippel-Lindau Syndrome.
What interventions are being tested in trial NCT01436227?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01436227?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01436227 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Hippel-Lindau Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.